|Description||LIK066 is a potent Sodium-glucose transporter 1 and Sodium-glucose transporter 2 inhibitor originated by Novartis Pharmaceuticals Corporation IC50 value is 22.0 nM against human SGLT1 and 0.5 nM against human SGLT2. In Apr 2016, Novartis completed a phase II trial for Type 2 diabetes mellitus in USA.|
|Synonyms||L-proline compound with (2S,3R,4R,5S,6R)-2-(3-((2,3-dihydrobenzo[b][1,4]dioxin-6-yl)methyl)-4-ethylphenyl)-6-(hydroxymethyl)tetrahydro-2H-pyran-3,4,5-triol (1:2)|
|Solubility||Soluble in DMSO|
|Application||Type 2 diabetes mellitus|
|Quality Standard||In-house standard|
|Shelf Life||2 month in rt, long time|
|Current Developer||Originator: Novartis Pharmaceuticals Corporation|
Dapagliflozin(BMS512148) is a selective, orally active inhibitor of the renal sodium-glucose co-transporter type 2 (SGLT2) is in development for the treatment o...
Dapagliflozin (2S)-1,2-propanediol, hydr
Dapagliflozin (2S)-1,2-propanediol, hydrate is a selective, orally active inhibitor of the renal sodium-glucose co-transporter type 2 (SGLT2). It is in developm...
EGT1442 is a potent and selective SGLT2 inhibitor with IC50 value of 5.6 μM /2 nM in SGLT1 /SGLT2 respectively. It significantly prolonged the median survival o...
Atigliflozin is a selective sodium-glucose co-transporter subtype 2 (SGLT2) inhibitor. It has antihyperglycemic activity and is used as an antihyperglycaemic dr...
LIK066 is a potent Sodium-glucose transporter 1 and Sodium-glucose transporter 2 inhibitor originated by Novartis Pharmaceuticals Corporation IC50 value is 22.0...
KGA2727 is a selective and potent SGLT1 inhibitor for the treatment of diabete. Its inhibition constant (Ki) values of 97 and 13,600 nM for human (h) SGLT1 and ...
Phlorizin is a 2'-glucoside of phloretin. It belongs to the group of dihydrochalcones, a type of flavonoids.
PF-04971729, a potent and selective inhibitor of the sodium-dependent glucose cotransporter 2, is currently in phase 2 trials for the treatment of diabetes mell...
TA-1887 is a selective Sodium Glucose Cotransporter 2 Inhibitor with pronounced antihyperglycemic effects in high-fat diet-fed KK (HF-KK) mice. It may be used f...
Canagliflozin hemihydrate is a highly potent and selective inhibitor of subtype 2 sodium-glucose transport protein (SGLT2), which is responsible for at least 90...
Mizagliflozin is a sodium-glucose transporter inhibitor. It is expected to improve postprandial hyperglycemia by suppressing glucose absorption from the intesti...
Canagliflozin is a sodium/glucose cotransporter 2 (SGLT2) inhibitor. Canagliflozin has been shown to dose dependently reduce calculated renal threshold for gluc...
Tofogliflozin(CSG-452) hydrate is a potent and highly specific sodium/glucose cotransporter 2(SGLT2) inhibitor with Ki values of 2.9, 14.9, and 6.4 nM for human...
Ipragliflozin is a highly potent and selective SGLT2 inhibitor and has little and NO potency for SGLT1/3/4/5/6.
hloretin is a dihydrochalcone, a type of natural phenols, which shows beneficial effects on diabetes.
Empagliflozin is a potent and selective SGLT-2 inhibitor with IC50 of 3.1 nM, exhibits >300-fold selectivity over SGLT-1, 4, 5 and 6.
Tofogliflozin is an experimental drug for the treatment of diabetes mellitus and is being developed by Chugai Pharma in collaboration with Kowa and Sanofi. It i...
LX-4211 is a potent dual SGLT2/1 inhibitor; Antidiabetic agents.